NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers

The study consists of of following phases: screening, induction, rest, challenge, and re-challenge (if necessary). The study will be conducted as a randomized, evaluator-blind test design.

Inclusion criteria

• Male or female subjects 18-65 years of age
• Has the ability to understand and has signed a written informed consent form and HIPAA authorization
• Females of childbearing potential must agree to use an adequate birth control
• Fitzpatrick (1988) skin type I, II, or III.

Exclusion criteria

• History of severe reactions from exposure to sunlight
• Known allergies or sensitivities to adhesives in patches, medical tape, or ingredients found in the test articles
• Inability to evaluate the skin in and around the test sites
• Diabetes requiring medication
• Clinical significant skin diseases which may contraindicate participation
• Asthma or any other severe respiratory disease requiring chronic medication
• Known immunological disorders such as HIV, AIDS, SLE and/or RA
• History, within the last six months, of current cancer, including skin cancer
• Mastectomy for cancer removal of lymph nodes draining test sites
• Epilepsy
• Pregnancy, lactation, or planning a pregnancy during the test period
• Chronic use of systemic antihistamine medication, or use within 14 days prior to Screening Visit
• Use of anti-inflammatory drugs (exception: acetaminophen and < 81 mg.day aspirin are permitted) within 2 days of Screening Visit
• Currently receiving allergy injections
• Currently taking or expecting to take any photosensitizing medications
• Use of immunosuppressive drugs
• Topical drugs used at the test sites within the last 7 days prior to screening
• Current participation in any clinical trial
• Participation in any patch test for irritation or sensitization or any test involving UV exposures within 4 wees of study start
• Use of any investigational therapy within the past 4 weeks.